Autopsy report · NCT02785900
Vadastuximab Talirine (SGN-CD33A; 33A) Combined With Azacitidine or Decitabine in Older Patients With Newly Diagnosed Acute Myeloid Leukemia
Cause of deathSafety
“Due to safety; specifically a higher rate of deaths, including fatal infections, in the SGN33A arm versus the control arm”
Life of this trial
- Ran for about 1 year 5 months before it stopped.
- 240 participants enrolled.
- Results were posted on the registry 1 year 2 months after it ended.
Vital statistics
- Status
- Terminated
- Phase
- Phase 3
- Sponsor
- Seagen Inc.
- Sponsor type
- Industry
- Conditions
- Acute Myeloid Leukemia
- Interventions
- 33A; placebo; azacitidine; decitabine
- Participants
- 240
- Sites
- 128
- Countries
- Australia, Austria, Belgium, Czechia, France, Germany, Hungary, Israel, Italy, Luxembourg, Poland, South Korea and more
Look deeper
- The official registry record (the source of truth)
- Record history: every change the sponsor made
- Open it in the database
Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.